Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia-CliniExpert
Forty Seven: Early Indications Suggest Magrolimab Could Be A Winner (NASDAQ:FTSV) | Seeking Alpha
Forty Seven: Buy The Dip In This CD47 Pioneer Ahead Of ASCO GI (NASDAQ:FTSV) | Seeking Alpha
ENHANCE-2 Trial of Magrolimab plus Azacitidine in AML
FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies | Business Wire
Magrolimab + Aza for AML - Slideset Download - Clinical Oncology 2022 | CCO
CD47-SIRPα Drug Target Minireview - Drug Hunter
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma | Future Oncology
Magrolimab plus azacitidine results in promising activity in higher-risk MDS patients
Efficacy of magrolimab + azacitidine in untreated AML and MDS patients. | Download Scientific Diagram
Efficacy of magrolimab + azacitidine in untreated AML and MDS patients. | Download Scientific Diagram
New Research on Magrolimab Provides Key Insights as Gilead Rapidly Expands Research in AML | Leukemia and Lymphoma Society
Forty Seven: Buy The Dip In This CD47 Pioneer Ahead Of ASCO GI (NASDAQ:FTSV) | Seeking Alpha
Forty Seven: Early Indications Suggest Magrolimab Could Be A Winner (NASDAQ:FTSV) | Seeking Alpha
Magrolimab Achieving Positive Results in Phase 1b Trial of Untreated AML
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy | Signal Transduction and Targeted Therapy
EHA Library - The official digital education library of European Hematology Association (EHA)
Cells | Free Full-Text | Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
ENHANCE-3 Trial of Magrolimab in Combination with Venetoclax and Azacitidine in AML
Corporate Overview
PhI/II AZA/VEN/MAG - Slideset Download - | CCO
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma - ScienceDirect
ASCO News - Magrolimab in Combination with Azacitidine Demonstrates Durable Activity in Untreated MDS & AML | Leukemia and Lymphoma Society
